SCG Cell Therapy Gets US FDA Nod to initiate Phase 1/2 trial for SCG142

SCG Cell Therapy Gets US FDA Nod to initiate Phase 1/2 trial for SCG142

By, Admin 3 July 2024

SCG Cell Therapy gets US FDA nod to initiate phase 1/2 trial for SCG142, a next-generation HPV-specific TCR T cell therapy for patients with HPV-associated solid tumour

Overview

SCG Cell Therapy Pte Ltd, a biotechnology company developing novel immunotherapies for infectious diseases and their associated cancers, announced that US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application to initiate phase 1/2 clinical trial for SCG142, a novel next-generation human papillomavirus (HPV) E7-specific T-cell receptor-engineered T (TCR T) cell therapy for patients with HPV-associated solid tumours.

Words from CEO: SCG Cell Therapy

  • This FDA IND approval of another TCR T cell therapy candidate generated from our proprietary GianTCR platform is an important milestone for SCG. It marks the advancement of our TCR-based therapeutic program to treat unmet needs in different major cancer indications"", said Christy Ma, CEO of SCG Cell Therapy. 
  • We are ready to commence multi-center phase 1/2 clinical trials, assessing the potential benefits for patients via our proprietary TCR T technology.

About SCG142

  • SCG142 is a high-avidity fully natural HPV-specific TCR armoured with a TGFßRII-41BB chimeric switch receptor. 
  • In May 2024, SCG presented preclinical data of SCG142 at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting. 
  • The data indicates SCG142 had exhibited high polyfunctional avidity. It recognized both HPV-16 and HPV-52 genotypes, with a favourable safety profile with no alloreactivity or off-target toxicity. 
  •  In addition, SCG142 demonstrated dual CD8 and CD4 TCR T cell proliferation and tumor inhibition in both in vitro and in vivo models, indicating CD8 co-receptor independent T cell functionality, as well as promoting long-term persistence of memory T cells.

Words from CSO: SCG Cell Therapy

  • SCG142 is a novel and differentiated HPV-specific TCR T cell therapy. By armoring the TCR T cells with the chimeric switch receptor, it overcomes the hostile tumor microenvironment and converts inhibitory effects into a co-stimulatory signal.
  • This process is essential for effective immunotherapy treatment of solid tumors. With this unique next-generation design, SCG142 represents a groundbreaking innovation that translates from our in-house discovery platforms into clinics"", said Dr. Ke Zhang, chief scientific officer of SCG Cell Therapy.

Human papillomavirus

  • Human papillomavirus (HPV) is the most common sexually transmitted infection. 
  • Nearly all sexually active people will be infected with HPV at some point in their lives. 
  • Approximately half of these infections are with a high-risk HPV type, which can lead to cancer. 
  • HPV infection accounts for more than 90% of anal and cervical cancers, about 70% of vaginal and vulvar cancers, and 60% of penile and oropharynx cancers. 
  • An estimated 630,000 new cancer cases and 350,000 deaths worldwide each year are resulted from HPV (related) infection.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!